Aaron E Miller
Affiliation: Mount Sinai School of Medicine
- Glatiramer acetate in the treatment of multiple sclerosisAaron E Miller
Department of Neurology, Mt Sinai School of Medicine, New York, NY, USA
Neurol Clin 23:215-31, viii. 2005
- Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosisAaron E Miller
Icahn School of Medicine at Mount Sinai, New York, New York Electronic address
Clin Ther 37:2366-80. 2015..The purpose was to summarize US prescribing information for teriflunomide in the treatment of patients with relapsing forms of multiple sclerosis (RMS), with reference to clinical efficacy and safety outcomes...
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trialAaron E Miller
Icahn School of Medicine at Mount Sinai, New York, NY, USA Electronic address
Lancet Neurol 13:977-86. 2014..We aimed to assess the efficacy and safety of teriflunomide in patients with a first clinical episode suggestive of multiple sclerosis...
- Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER studyAaron E Miller
Icahn School of Medicine at Mount Sinai, 5 East 98th Street, Box 1138, New York, NY, 10028, USA
J Neurol 261:1781-8. 2014..009) and had lower annualized rates of all hospitalizations (p = 0.030). Taken together, the positive effects of teriflunomide on severe relapses indicate that teriflunomide may reduce relapse-related healthcare costs. ..
- Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosisAaron E Miller
Mount Sinai School of Medicine, USA
Mult Scler 18:1625-32. 2012....
- Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needsAaron E Miller
Corinne Goldsmith Dikinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, New York 10029, USA
Curr Opin Neurol 25:S4-10. 2012....
- Multiple sclerosis: where will we be in 2020?Aaron E Miller
Mount Sinai School of Medicine, New York, NY, USA
Mt Sinai J Med 78:268-79. 2011..This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade...
- Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosisAaron Miller
Mount Sinai School of Medicine, New York, NY, USA
Mult Scler 14:494-9. 2008..0 reached EDSS >or= 6.0. Adverse events were similar to those reported in short-term clinical trials. This study shows a low rate of relapses and EDSS progression in RRMS patients on GA for up to 22 years...
- Immunotherapy of multiple sclerosis--current practice and future directionsMark J Tullman
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
J Rehabil Res Dev 39:273-85. 2002..Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure...
- Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trialJerry S Wolinsky
Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Ann Neurol 61:14-24. 2007..To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis...
- Defining the clinical course of multiple sclerosis: the 2013 revisionsFred D Lublin
From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis F D L, A E M, Icahn School of Medicine at Mount Sinai, New York, NY Scientific and Clinical Review Associates, LLC S C R, Salisbury, CT The Mellen Center for MS Treatment and Research J A C, R J F, R A R, Cleveland Clinic, OH the Department of Biostatistics G R C, University of Alabama at Birmingham the Danish Multiple Sclerosis Center P S S, Department of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark University College London Institute of Neurology A J T, UK the Department of Neurology J S W, J A L, University of Texas Health Sciences Center, Houston the Department of Neurology L J B, New York University Langone Medical Center, New York the Division of Neurology B Banwell, The Children s Hospital of Philadelphia, PA the Departments of Radiology and Nuclear Medicine F B and Neurology C H P, VU Medical Center, Amsterdam, the Netherlands Research Programs Department B Bebo, National Multiple Sclerosis Society, New York, NY the Department of Neurology P A C, The Johns Hopkins Hospital, Baltimore, MD Fédération de Neurologie M C, CHU Hôpital Purpan, Toulouse, France the Department of Neurology G C, Scientific Institute San Raffaele, Department of Pediatrics
Neurology 83:278-86. 2014..Strategies for future research to better define phenotypes are also outlined. ..
- Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trialKathleen Hawker
Department of Neurology, The Ohio State University Medical Center, Columbus, USA
Ann Neurol 66:460-71. 2009..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
- Dose comparison trial of sustained-release fampridine in multiple sclerosisA D Goodman
Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
Neurology 71:1134-41. 2008..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...